Akbar N Ashrafi1, Nima Nassiri1, Inderbir S Gill1, Mittul Gulati2, Daniel Park1, Andre L de Castro Abreu3. 1. USC Institute of Urology, Keck School of Medicine, University of Southern California, 1441 Eastlake Ave, Suite 7416, Los Angeles, CA, 90089, USA. 2. Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. 3. USC Institute of Urology, Keck School of Medicine, University of Southern California, 1441 Eastlake Ave, Suite 7416, Los Angeles, CA, 90089, USA. Andre.Abreu@med.usc.edu.
Abstract
PURPOSE OF REVIEW: Contrast-enhanced transrectal ultrasound (CeTRUS) is an emerging imaging technique in prostate cancer (PCa) diagnosis and treatment. We review the utility and implications of CeTRUS in PCa focal therapy (FT). RECENT FINDINGS: CeTRUS utilizes intravenous injection of ultrasound-enhancing agents followed by high-resolution ultrasound to evaluate tissue microvasculature and differentiate between benign tissue and PCa, with the latter demonstrating increased enhancement. The potential utility of CeTRUS in FT for PCa extends to pre-, intra- and post-operative settings. CeTRUS may detect PCa, facilitate targeted biopsy and aid surgical planning prior to FT. During FT, the treated area can be visualized as a well-demarcated non-enhancing zone and continuous real-time assessment allows immediate re-treatment if necessary. Following FT, the changes on CeTRUS are immediate and consistent, thus facilitating repeat imaging for comparison during follow-up. Areas suspicious for recurrence may be detected and target-biopsied. Enhancement can be quantified using time-intensity curves allowing objective assessment and comparison. Based on encouraging early outcomes, CeTRUS may become an alternative imaging modality in prostate cancer FT. Further study with larger cohorts and longer follow-up are needed.
PURPOSE OF REVIEW: Contrast-enhanced transrectal ultrasound (CeTRUS) is an emerging imaging technique in prostate cancer (PCa) diagnosis and treatment. We review the utility and implications of CeTRUS in PCa focal therapy (FT). RECENT FINDINGS: CeTRUS utilizes intravenous injection of ultrasound-enhancing agents followed by high-resolution ultrasound to evaluate tissue microvasculature and differentiate between benign tissue and PCa, with the latter demonstrating increased enhancement. The potential utility of CeTRUS in FT for PCa extends to pre-, intra- and post-operative settings. CeTRUS may detect PCa, facilitate targeted biopsy and aid surgical planning prior to FT. During FT, the treated area can be visualized as a well-demarcated non-enhancing zone and continuous real-time assessment allows immediate re-treatment if necessary. Following FT, the changes on CeTRUS are immediate and consistent, thus facilitating repeat imaging for comparison during follow-up. Areas suspicious for recurrence may be detected and target-biopsied. Enhancement can be quantified using time-intensity curves allowing objective assessment and comparison. Based on encouraging early outcomes, CeTRUS may become an alternative imaging modality in prostate cancer FT. Further study with larger cohorts and longer follow-up are needed.
Authors: J P Sedelaar; G J van Leenders; C A Hulsbergen-van de Kaa; H G van der Poel; J A van der Laak; F M Debruyne; H Wijkstra; J J de la Rosette Journal: Eur Urol Date: 2001-09 Impact factor: 20.096
Authors: L P Beyer; B Pregler; C Nießen; K Michalik; M Haimerl; C Stroszczynski; E M Jung; P Wiggermann Journal: Clin Hemorheol Microcirc Date: 2016 Impact factor: 2.375
Authors: B G Muller; W van den Bos; M Brausi; J J Fütterer; S Ghai; P A Pinto; I V Popeneciu; T M de Reijke; C Robertson; J J M C H de la Rosette; S Scionti; B Turkbey; H Wijkstra; O Ukimura; T J Polascik Journal: World J Urol Date: 2015-01-06 Impact factor: 4.226
Authors: Jeremy M Parker; Mark W Weller; Linda Maiman Feinstein; Robin J Adams; Michael L Main; Paul A Grayburn; David O Cosgrove; Barry A Goldberg; Kassa Darge; Petros Nihoyannopoulos; Stephanie Wilson; Mark Monaghan; Fabio Piscaglia; Brian Fowlkes; Wilson Mathias; Fuminari Moriyasu; Maria Christina Chammas; Lennard Greenbaum; Steven B Feinstein Journal: Am J Cardiol Date: 2013-06-28 Impact factor: 2.778
Authors: Alexander P S Kirkham; Mark Emberton; Ivan M Hoh; Rowland O Illing; A Alex Freeman; Clare Allen Journal: Radiology Date: 2008-01-25 Impact factor: 11.105
Authors: Friedrich Aigner; Leo Pallwein; Michael Mitterberger; Germar M Pinggera; Gregor Mikuz; Wolfgang Horninger; Ferdinand Frauscher Journal: BJU Int Date: 2008-11-18 Impact factor: 5.588
Authors: Rafael R Tourinho-Barbosa; Bradford J Wood; Andre Luis Abreu; Bruno Nahar; Toshitaka Shin; Selcuk Guven; Thomas J Polascik Journal: World J Urol Date: 2020-05-22 Impact factor: 4.226
Authors: Luke P O'Connor; Shayann Ramedani; Michael Daneshvar; Arvin K George; Andre Luis Abreu; Giovanni E Cacciamani; Amir H Lebastchi Journal: Asian J Urol Date: 2021-05-03
Authors: Indrani Bhattacharya; Yash S Khandwala; Sulaiman Vesal; Wei Shao; Qianye Yang; Simon J C Soerensen; Richard E Fan; Pejman Ghanouni; Christian A Kunder; James D Brooks; Yipeng Hu; Mirabela Rusu; Geoffrey A Sonn Journal: Ther Adv Urol Date: 2022-10-10